บทบาทของรังสีรักษาและเคมีบำบัดใน Rhabdomyosarcoma
Abstract
-
References
1. Friedmann AM, Tarbell NJ. Constine LS. Rhabomyosarcoma. In: Halperin EC, Constine LS, Tarbell NJ Kun LE, editors. Pediatric Radiation Oncology 4th ed. Philadelphia: Lippincott Williams & Wilkins;
2005. p. 319-46.
2. Breneman JC, Donaldson SS. Rhabdomyosarcoma. In: Halperin EC, Perez CA, Brady LW, editors. Perez and Brady's Principles and Practice of Radiation Oncology 5th ed. Philadelphia: Lippincott
Williams & Wilkins: 2008. p. 1872-85.
3. Tsuji SY, Chan LW, Haas-Kogan DA. Pediatric (Non-CNS) Tumors. In: Hansen EK, Roach III M, editors. Handbook of Evidence-Based Radiation Oncology 2nd ed. New York: Springer; 2010. p.
629-72.
4. Newton WA Jr, Gehan EA, Webber BL, Marsden HB, van Unnik AJ, Hamoudi AB, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new
classification-an Intergroup Rhabdomyosarcoma Study. Cancer 1995;76:1073-85.
5. Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988;61:209-20.
6. Maurer HM, Gehan EA, Beltangady M, Crist W, Dickman PS, Donaldson SS, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993;71:1904-22.
7. Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13:610-30.
8. Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, et al. Intergroup rhabdomyo-sarcoma study-IV: results for patients with nonmelastatic disease. J Clin Oncol 2001;19:3091-102.
9. Breitfeld PP, Lyden E, Raney RB, Teot LA, Wharam M, Labe T, et al. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered
with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Hematol Oncol 2001;23:225-33.
10. Raney RB, Anderson JR, Barr FG, Donaldsan SS, Pappo AS, Qualman SJ, et al. Rhabdomyósarcoma and Undifferentiated Sarcoma in the First Two Decades of Life: A Selective Review of Intergroup
Rhabdomyosarcoma Study Group Experience and Rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001;23:215-20.
11. Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, et al. Results st Intergroup Rhabdomyosarcoma Study Group D9602 Protocol, Using Vincristine and Dactinonne With or Without Cyclophosphamide and Radiation Therapy, for Newly Diagnosed Patients we Low-Risk Embryonal Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 2011:29:1312-8.
12. Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, et al. Vincristine Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803. J Clin Oncol 2009;27:5182-8.
13. Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, et al. Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With Vincristine for the Treatment of Metastatic
Rhabdomyosarcoma: The Children's Oncology Group. J Clin Oncol 2007:25:362-9.
14. Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, et al. Treatment of Nonmetastatic Rhabdomyosarcoma in Childhood and Adolescence: Third Study of the International Society of Paediatric Oncology-SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 2005;23:2618-28.
15. Donaldson SS, Anderson JR. Rhabdomyosarcoma: Many Similarities, a Few Philosophical Differences. J Clin Oncol 2005;23:2586-7.
16. Wolden SL, Anderson JR, Crist WM, Breneman JC, Wharam MD Jr, Wiener ES, et al. Indications for Radiotherapy and Chemotherapy After Complete Resection in Rhabdomyosarcoma: A Report From the Intergroup Rhabdomyosarcoma Studies I to II. J Clin Oncol 1999;17:3468-75.
17. Michalski JM, Meza J, Breneman JC, Wolden SL, Laurie F, Jodoin M, et al. Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials Il through IV. Int J Radiat Oncol Biol Phys 2004;59:1027-38.
18. Minn AY, Lyden ER, Anderson JR, Million L, Arndt CA, Brown K, et al. Early Treatment Failure in Intermediate-Risk Rhabdomyosarcoma: Results From IRS-IV and D9803-A Report From the Children's Oncology Group. J Clin Oncol 2010:28:4228-32.
2005. p. 319-46.
2. Breneman JC, Donaldson SS. Rhabdomyosarcoma. In: Halperin EC, Perez CA, Brady LW, editors. Perez and Brady's Principles and Practice of Radiation Oncology 5th ed. Philadelphia: Lippincott
Williams & Wilkins: 2008. p. 1872-85.
3. Tsuji SY, Chan LW, Haas-Kogan DA. Pediatric (Non-CNS) Tumors. In: Hansen EK, Roach III M, editors. Handbook of Evidence-Based Radiation Oncology 2nd ed. New York: Springer; 2010. p.
629-72.
4. Newton WA Jr, Gehan EA, Webber BL, Marsden HB, van Unnik AJ, Hamoudi AB, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new
classification-an Intergroup Rhabdomyosarcoma Study. Cancer 1995;76:1073-85.
5. Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988;61:209-20.
6. Maurer HM, Gehan EA, Beltangady M, Crist W, Dickman PS, Donaldson SS, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993;71:1904-22.
7. Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13:610-30.
8. Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, et al. Intergroup rhabdomyo-sarcoma study-IV: results for patients with nonmelastatic disease. J Clin Oncol 2001;19:3091-102.
9. Breitfeld PP, Lyden E, Raney RB, Teot LA, Wharam M, Labe T, et al. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered
with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Hematol Oncol 2001;23:225-33.
10. Raney RB, Anderson JR, Barr FG, Donaldsan SS, Pappo AS, Qualman SJ, et al. Rhabdomyósarcoma and Undifferentiated Sarcoma in the First Two Decades of Life: A Selective Review of Intergroup
Rhabdomyosarcoma Study Group Experience and Rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001;23:215-20.
11. Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, et al. Results st Intergroup Rhabdomyosarcoma Study Group D9602 Protocol, Using Vincristine and Dactinonne With or Without Cyclophosphamide and Radiation Therapy, for Newly Diagnosed Patients we Low-Risk Embryonal Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 2011:29:1312-8.
12. Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, et al. Vincristine Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803. J Clin Oncol 2009;27:5182-8.
13. Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, et al. Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With Vincristine for the Treatment of Metastatic
Rhabdomyosarcoma: The Children's Oncology Group. J Clin Oncol 2007:25:362-9.
14. Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, et al. Treatment of Nonmetastatic Rhabdomyosarcoma in Childhood and Adolescence: Third Study of the International Society of Paediatric Oncology-SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 2005;23:2618-28.
15. Donaldson SS, Anderson JR. Rhabdomyosarcoma: Many Similarities, a Few Philosophical Differences. J Clin Oncol 2005;23:2586-7.
16. Wolden SL, Anderson JR, Crist WM, Breneman JC, Wharam MD Jr, Wiener ES, et al. Indications for Radiotherapy and Chemotherapy After Complete Resection in Rhabdomyosarcoma: A Report From the Intergroup Rhabdomyosarcoma Studies I to II. J Clin Oncol 1999;17:3468-75.
17. Michalski JM, Meza J, Breneman JC, Wolden SL, Laurie F, Jodoin M, et al. Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials Il through IV. Int J Radiat Oncol Biol Phys 2004;59:1027-38.
18. Minn AY, Lyden ER, Anderson JR, Million L, Arndt CA, Brown K, et al. Early Treatment Failure in Intermediate-Risk Rhabdomyosarcoma: Results From IRS-IV and D9803-A Report From the Children's Oncology Group. J Clin Oncol 2010:28:4228-32.
Downloads
Published
2020-01-23
How to Cite
1.
รายยวา น. บทบาทของรังสีรักษาและเคมีบำบัดใน Rhabdomyosarcoma. J Thai Assn of Radiat Oncol [Internet]. 2020 Jan. 23 [cited 2024 May 7];18(2):21-8. Available from: https://he01.tci-thaijo.org/index.php/jtaro/article/view/236579
Issue
Section
Review articles
License
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของวารสารมะเร็งวิวัฒน์ ข้อความที่ปรากฏในบทความแต่ละเรื่องในวารสารวิชาการเล่มนี้เป็นความคิดเห็นส่วนตัวของผู้เขียนแต่ละท่านไม่เกี่ยวข้องกับ และบุคคลากรท่านอื่น ๆ ใน สมาคมฯ แต่อย่างใด ความรับผิดชอบองค์ประกอบทั้งหมดของบทความแต่ละเรื่องเป็นของผู้เขียนแต่ละท่าน หากมีความผิดพลาดใดๆ ผู้เขียนแต่ละท่านจะรับผิดชอบบทความของตนเองแต่ผู้เดียว
